Immune Induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice
【Abstract】
Heat-killed antigen with or without adjuvant was evaluated as a vaccine candidate in murine model.
Two adjuvants (AddaVax and Montanide ISA 201) were tested for enhancing the efficacy of vaccines for the first time against visceral leishmaniasis.
Th1 biased immune response was generated in immunized mice.
All the vaccine candidates were protective against Leishmania donovani infection.
Study showed the potential of adjuvants in enhancing the protection by vaccines.
Visceral leishmaniasis (VL) is a neglected tropical disease caused by Leishmania donovani or Leishmania infantum. Currently, the patients are treated with chemotherapeutic drugs; however, their toxicity limits their use. It would be desirable to develop a vaccine against this infection. In this study, we assessed the efficacy of different vaccine formulations at variable time points. Heat-killed (HK) antigen of Leishmania donovani was adjuvanted with two adjuvants (AddaVax and Montanide ISA 201) and three immunizations at a gap of 2 weeks (wk) were given to BALB/c mice. After 2 weeks of the last booster, mice were given challenge infection and sacrificed before challenge and after 4wk, 8wk, and 12 wk post-challenge. Significant protective immunity was observed in all the immunized animals and it was indicated by the notable rise in delayed-type hypersensitivity (DTH) response, remarkably declined parasite burden, a significant increase in the levels of interferon-gamma (IFN-γ), interleukin-12, interleukin-17 (Th1 cytokines), and IgG2a in contrast to infected control mice. Montanide ISA 201 with HK antigen provided maximum protection followed by AddaVax with HK and then HK alone. These findings elaborate on the importance of the tested adjuvants in the vaccine formulations against murine visceral leishmaniasis.
【Author】
DeepakKumar Goyal, PoonamKeshav, SukhbirKaur
【Keywords】
Visceral leishmaniasis, Heat-killed antigen, adjuvant, vaccine, AddaVax, Montanide ISA 201 
【Journal】
Immunobiology(IF：2.8) Time：2021-01-24
